| Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy JML Ebos, CR Lee, JG Christensen, AJ Mutsaers, RS Kerbel Proceedings of the National Academy of Sciences 104 (43), 17069-17074, 2007 | 469 | 2007 |
| Canine transitional cell carcinoma AJ Mutsaers, WR Widmer, DW Knapp Journal of veterinary internal medicine 17 (2), 136-144, 2003 | 352 | 2003 |
| Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer SI Mohammed, PF Bennett, BA Craig, NW Glickman, AJ Mutsaers, ... Cancer research 62 (2), 356-358, 2002 | 259 | 2002 |
| Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? AJ Mutsaers, CR Walkley Bone 62, 56-63, 2014 | 252 | 2014 |
| Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs PA Boria, DJ Murry, PF Bennett, NW Glickman, PW Snyder, BL Merkel, ... Journal of the American Veterinary Medical Association 224 (3), 388-394, 2004 | 178 | 2004 |
| Vascular endothelial growth factor–mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth JML Ebos, CR Lee, E Bogdanovic, J Alami, P Van Slyke, G Francia, P Xu, ... Cancer research 68 (2), 521-529, 2008 | 141 | 2008 |
| Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder PA Boria, NW Glickman, BR Schmidt, WR Widmer, AJ Mutsaers, ... Veterinary and Comparative Oncology 3 (2), 73-80, 2005 | 125 | 2005 |
| Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2 R Mamluk, IM Carvajal, BA Morse, HK Wong, J Abramowitz, S Aslanian, ... MAbs 2 (2), 199-208, 2010 | 124 | 2010 |
| Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary … SI Mohammed, BA Craig, AJ Mutsaers, NW Glickman, PW Snyder, ... Molecular cancer therapeutics 2 (2), 183-188, 2003 | 121 | 2003 |
| Metronomic chemotherapy AJ Mutsaers Topics in companion animal medicine 24 (3), 137-143, 2009 | 101 | 2009 |
| Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam V Langova, AJ Mutsaers, B Phillips, R Straw Australian veterinary journal 82 (11), 676-680, 2004 | 91 | 2004 |
| Modeling distinct osteosarcoma subtypes in vivo using Cre: lox and lineage-restricted transgenic shRNA AJ Mutsaers, AJM Ng, EK Baker, MR Russell, AM Chalk, M Wall, ... Bone 55 (1), 166-178, 2013 | 83 | 2013 |
| Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma A Gupte, EK Baker, SS Wan, E Stewart, A Loh, AA Shelat, CM Gould, ... Clinical Cancer Research 21 (14), 3216-3229, 2015 | 72 | 2015 |
| Synthesis of curcumin-functionalized gold nanoparticles and cytotoxicity studies in human prostate cancer cell line S Nambiar, E Osei, A Fleck, J Darko, AJ Mutsaers, S Wettig Applied Nanoscience 8, 347-357, 2018 | 71 | 2018 |
| Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs AJ Mutsaers, NW Glickman, DB DeNicola, WR Widmer, PL Bonney, ... Journal of the American Veterinary Medical Association 220 (12), 1813-1817, 2002 | 71 | 2002 |
| Preclinical mouse models of osteosarcoma Ö Uluçkan, A Segaliny, S Botter, JM Santiago, AJ Mutsaers BoneKEy reports 4, 2015 | 53 | 2015 |
| Biodistribution and physiologically-based pharmacokinetic modeling of gold nanoparticles in mice with interspecies extrapolation M Aborig, PRV Malik, S Nambiar, P Chelle, J Darko, A Mutsaers, ... Pharmaceutics 11 (4), 179, 2019 | 52 | 2019 |
| Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs J Calvalido, GA Wood, AJ Mutsaers, D Wood, W Sears, JP Woods Veterinary immunology and immunopathology 182, 106-114, 2016 | 52 | 2016 |
| Dose-dependent increases in circulating TGF-α and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent AJ Mutsaers, G Francia, S Man, CR Lee, JML Ebos, Y Wu, L Witte, S Berry, ... Clinical Cancer Research 15 (7), 2397-2405, 2009 | 52 | 2009 |
| Genetically engineered mouse models and human osteosarcoma AJM Ng, AJ Mutsaers, EK Baker, CR Walkley Clinical sarcoma research 2, 1-14, 2012 | 48 | 2012 |
